N-Terminal Pro–Atrial Natriuretic Peptide Measurement in Plasma Suggests Covalent Modification
Authors:
- 1 September 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 57 (9) , 1327-1330
Abstract
BACKGROUND: The N-terminal fragment of cardiac-derived pro–B-type natriuretic peptide is a glycosylated polypeptide. It is unknown whether N-terminal pro–atrial natriuretic peptide (proANP) fragments are also covalently modified. We therefore evaluated the clinical performance of 2 distinctly different proANP assays on clinical outcome. METHODS: We examined 474 elderly patients with symptoms of heart failure presenting in a primary healthcare setting. Samples were analyzed with an automated immunoluminometric midregion proANP (MR-proANP) assay and a new processing-independent assay (PIA) developed in our laboratory. The results were compared with Bland–Altman plots, and clinical performance was assessed by generating ROC curves for different clinical outcomes. RESULTS: Despite linear regression results indicating a good correlation (r = 0.85; P < 0.0001), the PIA measured considerably more proANP than the MR-proANP assay (mean difference, 663 pmol/L; SD, 478 pmol/L). In contrast, the clinical performances of the 2 assays [as assessed by the area under the ROC curve (AUC)] in detecting left ventricular dysfunction were similar [proANP PIA, 0.71 (95% CI, 0.63–0.79); MR-proANP assay, 0.74 (95% CI, 0.66–0.81); P = 0.32]. The prognostic ability to report cardiovascular mortality during a 10-year follow-up revealed AUC values of 0.66 (95% CI, 0.60–0.71) for the proANP PIA and 0.69 (95% CI, 0.63–0.74) for the MR-proANP assay (P = 0.08, for comparing the 2 assays). CONCLUSIONS: Our data suggest that N-terminal proANP fragments in patient plasma differ from the calibrator peptides used but that the difference does not affect ROC curves in an elderly cohort of patients with mild to moderate heart failure. We suggest that human N-terminal proANP fragments can be covalently modified.Keywords
Funding Information
- Rigshospitalets Forskningsråd
This publication has 13 references indexed in Scilit:
- Effect of Sialylated O-Glycans in Pro–Brain Natriuretic Peptide StabilityClinical Chemistry, 2010
- Peptide Hormones and their Prohormones as BiomarkersBiomarkers in Medicine, 2009
- Processing of Pro–Brain Natriuretic Peptide Is Suppressed by O-Glycosylation in the Region Close to the Cleavage SiteClinical Chemistry, 2009
- Impact of Epitope Specificity and Precursor Maturation in Pro-B–Type Natriuretic Peptide MeasurementClinical Chemistry, 2008
- Cross-Reactivity of BNP, NT-proBNP, and proBNP in Commercial BNP and NT-proBNP Assays: Preliminary Observations from the IFCC Committee for Standardization of Markers of Cardiac DamageClinical Chemistry, 2008
- The human cardiac hormone fragment N-terminal pro B-type natriuretic peptide is an intrinsically unstructured proteinArchives of Biochemistry and Biophysics, 2007
- The risk of cardiovascular death in elderly patients with possible heart failure. Results from a 6-year follow-up of a Swedish primary care populationInternational Journal of Cardiology, 2005
- Immunoluminometric Assay for the Midregion of Pro-Atrial Natriuretic Peptide in Human PlasmaClinical Chemistry, 2004
- The Posttranslational Phase of Gene Expression: New Possibilities in Molecular DiagnosisCurrent Molecular Medicine, 2003
- The Amino Terminal Regions of proBNP and proANP Oligomerise through Leucine Zipper-like Coiled-coil MotifsBiochemical and Biophysical Research Communications, 1999